EGFR and non-small cell lung carcinoma: In NSCLC, specific EGFR mutations such as exon 19 deletions or exon 21 mutations (L858R), render tumors sensitive to EGFR TKIs, whereas an exon 20 mutation (T790M) is associated with therapeutic resistance.[29] A similar scenario is possible for other oncogenic mutations.